McGlashan T H
Department of Psychiatry, Yale University School of Medicine, P.O. Box 208098, New Haven, CT 06520-8098, USA.
Schizophr Res. 2001 Aug 1;51(1):47-54. doi: 10.1016/s0920-9964(01)00238-9.
Clinical trials have begun of antipsychotic treatments in persons who are prodromally symptomatic and at high risk for schizophrenia but who have not yet become psychotic. The ethical issues connected with intervening prior to making a diagnosis of psychosis are detailed. Compelling but tentative evidence suggests that early treatment may improve course and prognosis, and this has initiated a paradigm shift in thinking about the risks and benefits of early intervention. The nature of this evidence, its implications, its shortcomings, and its effect upon the ethics of treating schizophrenia are elaborated and discussed. It is concluded that clinical psychiatry is currently in a state of "equipoise" or genuine uncertainty about the comparative merits of early treatment, a state which endorses early intervention research, including intervention in the prodromal phase.
针对处于精神分裂症前驱症状且高危但尚未出现精神病性症状的人群,抗精神病治疗的临床试验已经开始。文中详细阐述了在做出精神病诊断之前进行干预所涉及的伦理问题。有力但尚不完善的证据表明,早期治疗可能改善病程和预后,这引发了对于早期干预风险和益处的思维模式转变。本文对该证据的性质、其影响、不足之处以及对精神分裂症治疗伦理的作用进行了阐述和讨论。得出的结论是,临床精神病学目前对于早期治疗的相对优势处于“ equipoise”状态或真正的不确定状态,这种状态支持早期干预研究,包括在前驱期进行干预。